MA27805A1 - Cristaux de derive de benzimidazole et leur procede de preparation - Google Patents

Cristaux de derive de benzimidazole et leur procede de preparation

Info

Publication number
MA27805A1
MA27805A1 MA28603A MA28603A MA27805A1 MA 27805 A1 MA27805 A1 MA 27805A1 MA 28603 A MA28603 A MA 28603A MA 28603 A MA28603 A MA 28603A MA 27805 A1 MA27805 A1 MA 27805A1
Authority
MA
Morocco
Prior art keywords
preparing
same
benzimidazole derivative
derivative crystals
crystals
Prior art date
Application number
MA28603A
Other languages
English (en)
Inventor
Mitsuru Teramoto
Naoki Tsuchiya
Hiroshi Saitoh
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA27805A1 publication Critical patent/MA27805A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ABSTRAIT Les diverses formes en cristal de l'acide butanoïque 4-(l-((4, methylbenzothiophen-3-yl) méthyle) benzimidazol-2 ylthio) à partir du solvant, et du procédé pour la production de celui-ci sont fournies.
MA28603A 2003-05-14 2005-11-14 Cristaux de derive de benzimidazole et leur procede de preparation MA27805A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14

Publications (1)

Publication Number Publication Date
MA27805A1 true MA27805A1 (fr) 2006-03-01

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28603A MA27805A1 (fr) 2003-05-14 2005-11-14 Cristaux de derive de benzimidazole et leur procede de preparation

Country Status (25)

Country Link
US (1) US7649008B2 (fr)
EP (1) EP1626048A4 (fr)
JP (1) JPWO2004101551A1 (fr)
KR (1) KR20060011997A (fr)
CN (1) CN1788007A (fr)
AR (1) AR044340A1 (fr)
AU (1) AU2004238708A1 (fr)
BR (1) BRPI0410266A (fr)
CA (1) CA2523978A1 (fr)
CL (1) CL2004001034A1 (fr)
CO (1) CO5660259A2 (fr)
EC (1) ECSP056162A (fr)
IS (1) IS8177A (fr)
MA (1) MA27805A1 (fr)
MX (1) MXPA05011851A (fr)
NO (1) NO20055181L (fr)
NZ (1) NZ542978A (fr)
PE (1) PE20050203A1 (fr)
RU (1) RU2332417C2 (fr)
SA (1) SA04250117B1 (fr)
TN (1) TNSN05288A1 (fr)
TW (1) TW200505911A (fr)
UA (1) UA81493C2 (fr)
WO (1) WO2004101551A1 (fr)
ZA (1) ZA200508640B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
JP4387360B2 (ja) * 2003-08-22 2009-12-16 帝人ファーマ株式会社 キマーゼ阻害剤を有効成分として含有する薬剤
WO2006052026A1 (fr) * 2004-11-12 2006-05-18 Teijin Pharma Limited Sel acide de derive de benzimidazole et cristal dudit sel
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72244T1 (de) 1986-03-21 1992-02-15 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
WO1995032943A1 (fr) 1994-05-31 1995-12-07 Teijin Limited Derive de naphthalene
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
TR200100047T2 (tr) 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
PT1249450E (pt) * 2000-01-17 2008-01-02 Teijin Pharma Ltd Derivados de benzimidazole como inibidores de quimase humana
AU2002233698B2 (en) * 2001-02-22 2007-11-08 Teijin Limited Benzo(b)thiophene derivative and process for producing the same
CN1205204C (zh) * 2001-05-07 2005-06-08 帝人株式会社 3－羟甲基－苯并[b]噻吩衍生物及其制备方法
KR100902799B1 (ko) 2001-08-24 2009-06-12 데이진 가부시키가이샤 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
SA04250117B1 (ar) 2009-09-02
US20060293375A1 (en) 2006-12-28
RU2332417C2 (ru) 2008-08-27
WO2004101551A1 (fr) 2004-11-25
US7649008B2 (en) 2010-01-19
BRPI0410266A (pt) 2006-05-16
NO20055181L (no) 2006-01-24
EP1626048A4 (fr) 2008-11-12
CL2004001034A1 (es) 2005-03-28
AU2004238708A1 (en) 2004-11-25
NZ542978A (en) 2009-04-30
TW200505911A (en) 2005-02-16
AR044340A1 (es) 2005-09-07
TNSN05288A1 (en) 2007-07-10
PE20050203A1 (es) 2005-03-26
EP1626048A1 (fr) 2006-02-15
KR20060011997A (ko) 2006-02-06
JPWO2004101551A1 (ja) 2006-07-13
CA2523978A1 (fr) 2004-11-25
MXPA05011851A (es) 2006-02-17
UA81493C2 (en) 2008-01-10
CO5660259A2 (es) 2006-07-31
IS8177A (is) 2005-12-13
RU2005138868A (ru) 2006-07-10
NO20055181D0 (no) 2005-11-03
CN1788007A (zh) 2006-06-14
ZA200508640B (en) 2007-02-28
ECSP056162A (es) 2006-04-19

Similar Documents

Publication Publication Date Title
EA200601584A1 (ru) Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
ATE332686T1 (de) Verfahren zum herstellen von kristallen, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen
DE50307267D1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
NO20085077L (no) Nye forbindelser
SE0102300D0 (sv) Compounds
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
NO20062370L (no) Amidderivater
CL2007001286A1 (es) Procedimiento para preparar amidas aromaticas del acido crotonico por formacion delcloruro de acido correspondiente y amidacion posterior.
MA27069A1 (fr) FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
MA27805A1 (fr) Cristaux de derive de benzimidazole et leur procede de preparation
NO20044041L (no) Okso-azabisykliske forbindelser
ATE386725T1 (de) Heterocyclylverbindungen
UY24504A1 (es) Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
JP2008540665A (ja) イオンチャネルのモジュレーターとして有用なビアリール
DE69207301T2 (de) Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde
DE50311923D1 (de) Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE487478T1 (de) Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
ME00057B (me) Novi derivati morfolina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
CN101939306A (zh) 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐
BRPI0413617A (pt) polimorfo cristalino, composição, processo para preparação do polimorfo cristalino, composição farmacêutica, e, método para o tratamento de distúrbios do sistema nervoso central
BR0307880A (pt) Método para purificar um composto de nióbio e/ou um composto de tântalo altamente puro